Polyclonal on- and off-target resistance mutations in an
ALK
ALK inhibitors
KRAS
NSCLC
resistance mutations
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
14 Sep 2021
14 Sep 2021
Historique:
received:
25
06
2021
accepted:
18
08
2021
entrez:
22
9
2021
pubmed:
23
9
2021
medline:
23
9
2021
Statut:
epublish
Résumé
Treatment of advanced stage
Identifiants
pubmed: 34548910
doi: 10.18632/oncotarget.28062
pii: 28062
pmc: PMC8448518
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1946-1952Informations de copyright
Copyright: © 2021 Kemper et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
Références
Clin Cancer Res. 2012 Nov 15;18(22):6219-26
pubmed: 22843788
Lancet Oncol. 2015 Jul;16(7):e342-51
pubmed: 26149886
Lancet Respir Med. 2019 May;7(5):387-401
pubmed: 30922878
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
BMC Cancer. 2020 Dec 3;20(1):1185
pubmed: 33272262
J Thorac Oncol. 2018 Oct;13(10):1530-1538
pubmed: 29935304
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
EClinicalMedicine. 2021 Jun 26;38:100990
pubmed: 34505024
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Science. 2014 Dec 19;346(6216):1480-6
pubmed: 25394791
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Mol Cancer Res. 2017 Jan;15(1):106-114
pubmed: 27707887
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
N Engl J Med. 2020 Nov 19;383(21):2018-2029
pubmed: 33207094
Cancer Cell. 2015 Mar 9;27(3):397-408
pubmed: 25759024
Clin Cancer Res. 2019 Nov 15;25(22):6671-6682
pubmed: 31439588
Cancers (Basel). 2017 Sep 05;9(9):
pubmed: 28872581
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
World J Surg Oncol. 2020 Jan 20;18(1):15
pubmed: 31959178
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Clin Lung Cancer. 2017 Nov;18(6):692-697
pubmed: 28601386
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Clin Cancer Res. 2012 Mar 1;18(5):1472-82
pubmed: 22235099
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):603-6
pubmed: 23157828
Nat Med. 2015 Sep;21(9):1038-47
pubmed: 26301689
Cancer Sci. 2020 Jan;111(1):266-278
pubmed: 31746520
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Clin Oncol. 2019 Jun 1;37(16):1370-1379
pubmed: 30892989
Nat Med. 2014 Sep;20(9):1027-34
pubmed: 25173427
N Engl J Med. 2020 Aug 27;383(9):813-824
pubmed: 32846060
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
J Pharmacol Exp Ther. 2020 Jul;374(1):134-140
pubmed: 32284325
J Thorac Oncol. 2019 Nov;14(11):1901-1911
pubmed: 31446141
Clin Cancer Res. 2018 Jul 15;24(14):3334-3347
pubmed: 29636358
N Engl J Med. 2020 Oct 29;383(18):1711-1723
pubmed: 32955177
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378
Int J Oncol. 2017 Nov;51(5):1533-1540
pubmed: 29048652
Clin Cancer Res. 2020 Jun 1;26(11):2535-2545
pubmed: 32086345
Mol Cancer Ther. 2016 Jan;15(1):162-71
pubmed: 26682573
Sci Transl Med. 2012 Feb 8;4(120):120ra17
pubmed: 22277784